These days, Biotherapeutics are the rapidly growing group of pharmaceuticals, actually for a treatment option, a variety of chronic and sometimes life-threatening conditions. Those represent a dissimilar group of biological preparations that widely encompasses nucleic acids, proteins, whole cells, viral particles, and vaccines.
In recent years, great progress has been made regarding the development of safe and effective Biotherapeutics, and in the adoption of cost-effective, more efficient, and modernized manufacturing processes. This trend looks forward to accelerating in the forthcoming years, as emerging fields related to advanced therapies or personalized medicine mature.
Advances in Drug Discovery and Development
Any Procedure which is applied to drug discovery and development by the medical community and pharmaceutical industry has a direct change in the further availability of better, innovative, and therapeutic treatment for patients with cancer. Drug discovery is defined as a complicated learning technique whereby research efforts are directed towards discover and assimilating new innovative thoughts to produce a drug to provide a benefit to a patient population.
Subsequently, a highly useful technology or approach to drug discovery should give both effective thoughts and the applications of newly discovered observations that can be utilized for therapeutic benefit.
Important Alert:
X
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Why we need to advance from data focus to knowledge focus for managing healthcare transformation?
Bernd Blobel, University of Regensburg, Germany
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Unveiling the binding interactions of selected antimalarial drugs with major plasma transporter
Saad Tayyab, UCSI University, Malaysia
Title : Pharmacokinetic properties of TNX-102 SL, a sublingual formulation of cyclobenzaprine hydrochloride
Bruce Daugherty, Tonix Pharmaceuticals, United States
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Photodegradation of two pharmaceutical namely levofloxacin and atorvastatin via Chitosan/Ag/TiO2 3D printed scaffold
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Mannitol as eutectic forming agent for improved sublingual delivery of Cyclobenzaprine HCl
Marino Nebuloni, University of Insubria, Italy
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States